The historic rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its legacy within the broader sector now triggers questions about long-term returns . Alternative versions are diminishing patent protection , leading to worries that betting on companies closely tied to Viagra's previous position could be a speculative